[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-364503-105":59,"doc-detail-364503-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","impact-of-upper-tract-urothelial-carcinoma-history-on-patients-with-non-muscle-invasive-bladder-cancer-undergoing-intravesical-chemotherapy","Impact of upper tract urothelial carcinoma history on patients with non-muscle invasive bladder cancer undergoing intravesical chemotherapy","","A single-center retrospective cohort study evaluated whether a history of upper tract urothelial carcinoma (UTUC) influences prognosis in patients with non-muscle-invasive bladder cancer (NMIBC) treated with intravesical chemotherapy. Among 444 NMIBC patients receiving chemotherapy after TURBT at Peking University People’s Hospital (2000–2015), 34 had prior UTUC and 410 were primary NMIBC. UTUC history correlated with older age, more multiple tumors, higher recurrence, and worse recurrence-free survival. Cox regression identified UTUC history as an independent recurrence risk factor, particularly with a ≤24-month interval between UTUC and NMIBC diagnoses.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/impact-of-upper-tract-urothelial-carcinoma-history-on-patients-with-non-muscle-invasive-bladder-cancer-undergoing-intravesical-chemotherapy/364503/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/impact-of-upper-tract-urothelial-carcinoma-history-on-patients-with-non-muscle-invasive-bladder-cancer-undergoing-intravesical-chemotherapy/364503.png","ImageObject",300,407,{"name":92,"@type":93},"Aria","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What question does the study address about UTUC history and NMIBC?","Question",{"text":112,"@type":113},"It evaluates how a prior upper tract urothelial carcinoma (UTUC) history affects prognosis in NMIBC patients receiving intravesical chemotherapy.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were patients grouped in the retrospective cohort study?",{"text":117,"@type":113},"Patients were divided into a UTUC-NMIBC group (UTUC history) and a primary NMIBC group (no UTUC history) based on previous UTUC presence.",{"name":119,"@type":110,"acceptedAnswer":120},"What statistical methods were used to assess recurrence and progression outcomes?",{"text":121,"@type":113},"Kaplan–Meier curves with log-rank tests compared recurrence-free survival (RFS) and progression-free survival (PFS) between groups, and multivariable Cox regression identified variables associated with RFS and PFS.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},364503,1790791437,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":34,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},2336464648322,"https://ap-avatar.wpscdn.com/avatar/2200025388227c56fec?_k=1778556882303663488","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nImpact of upper tract urothelial carcinoma history on patients with non-muscle invasive bladder cancer undergoing intravesical chemotherapy  \nJiaxiang Ji1,2,4, Fei Wang3,4, Chin-Hui Lai1,2,4, Mingrui Wang1,2, Haopu Hu1,2, Kexin Xu1,2, Tao Xu1,2 & Hao Hu1,2􀀍  \nThis study was designed to evaluate the impact of upper tract urothelial carcinoma (UTUC) history on prognosis in patients with non-muscle-invasive bladder cancer (NMIBC) receiving intravesical chemotherapy. We conducted a single center, retrospective, cohort study of 444 NMIBC patients who received intravesical chemotherapy after transurethral resection of the bladder cancer (TURBT) at Peking University People’s Hospital from 2000 to 2015. Patients were divided into UTUC-NMIBC group (with UTUC history) and primary NMIBC group (without UTUC history) by presence of previous  \nUTUC. Demographic, clinical and pathologic factors were analyzed. Kaplan–Meier curves and the log-rank test were used to depict and compare recurrence-free survival (RFS) and progression-free survival (PFS) between the two groups. Multivariable Cox regression models were constructed to determine the variables associated with RFS and PFS. Compared to the primary NMIBC group (n = 410), the UTUC-NMIBC group (n = 34) had an older median age [72.0 (65.0–81.0) vs. 66.0 (58–75) years;  \nP = 0.007], a higher incidence of multiple tumors (52.9% vs. 33.9%; P = 0.026) and a higher recurrence rate (52.9% vs. 30.7%; P = 0.008) and worse RFS (P \u003C 0.001). In multivariate analysis, UTUC history was an independent risk factor for recurrence (hazard ratio = 2.242; P = 0.001), but not for progression. Interestingly, subgroup analysis indicated patients with recent UTUC history (≤ 24 months between UTUC and NMIBC diagnoses) were associated with increased recurrence rates (73.7% vs. 26.7%;  \nP = 0.014). Presence of UTUC history was an independent risk factor for recurrence in patients with NMIBC who received intravesical chemotherapy, especially in those with a shorter interval between UTUC and NMIBC diagnoses.  \nBladder cancer (BC), as one of the most prevalent genitourinary malignancies, accounts for an estimated 500 000 new cases and 200 000 deaths annually worldwide1. About 75% patients are initially diagnosed as nonmuscle invasive bladder cancer (NMIBC) with mucosal or submucosal confined disease2. In spite of undergoing transurethral resection of the bladder tumor (TURBT) and adjuvant intravesical therapy including chemotherapy or immunotherapy, disease recurrence and progression remain prevalent, which aggravate the burden of healthcare system and prompt researchers’ widespread attention3.  \nVarious predictive models have been established to stratify recurrence and progression risk, among which the European Organisation for Research and Treatment of Cancer (EORTC) and Club Urologico Espanol de Tratamiento Oncologico(CUETO) scoring systems are widely adopted, taking into account risk factors including tumor size, tumor multiplicity, age, carcinoma in situ (CIS), tumor grade, tumor stage, and previous  \n3–6 recurrence .  \nUpper tract urothelial carcinoma (UTUC) stands as a relatively uncommon malignancy, encompassing roughly 5–10% of urothelial carcinomas7. Patients with UTUC history exhibit an augmented risk of intravesical recurrence(IVR), with subsequent BCa occurring in 15–50% of patients who undergo radical  \n1Department of Urology, Peking University People’s Hospital, Beijing, China. 2The Institute of Applied Lithotripsy Technology, Peking University, Beijing, China. 3Department of Urology, Beijing Jishuitan Hospital Affiliated to Capital Medical University, Beijing, China. 4Jiaxiang Ji, Fei Wang and Chin-Hui Lai contributed equally to this manuscript and shared co-first authors. 􀀍 email: [huhao@bjmu.edu.cn](huhao@bjmu.edu.cn)  \n[www. nature.com/scientificreports/](www. nature.com/scientificreports/)  \nnephroureterectomy8. However, ","cbCaif5OWkuDjDdv","https://ap.wps.com/l/cbCaif5OWkuDjDdv","pdf",1422519,"English","# Patients and methods\n## Study design and groups\n## Intravesical chemotherapy definition and follow-up\n## Outcomes and statistical analyses","[{\"question\":\"What question does the study address about UTUC history and NMIBC?\",\"answer\":\"It evaluates how a prior upper tract urothelial carcinoma (UTUC) history affects prognosis in NMIBC patients receiving intravesical chemotherapy.\"},{\"question\":\"How were patients grouped in the retrospective cohort study?\",\"answer\":\"Patients were divided into a UTUC-NMIBC group (UTUC history) and a primary NMIBC group (no UTUC history) based on previous UTUC presence.\"},{\"question\":\"What statistical methods were used to assess recurrence and progression outcomes?\",\"answer\":\"Kaplan–Meier curves with log-rank tests compared recurrence-free survival (RFS) and progression-free survival (PFS) between groups, and multivariable Cox regression identified variables associated with RFS and PFS.\"}]","Impact of upper tract urothelial carcinoma history on patients with non-muscle invasive bladder cancer undergoing intravesical chemotherapy | PDF",1790157837,18,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dd8a6bd2c3c3f43a67988c40e675ccaf.webp",983,1291,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0ed448a5db913b07946fee0e7f4e6880.webp",982,1290,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/729f764ad9dac755029bbc4254c86489.webp",981,1289,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d2be8ae9efe3dd85e79a066ce6a2168c.webp",980,1287]